- Home
- NBIX
as 05-17-2024 4:00pm EST
$.
+$.
+.%
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 13.8B | IPO Year: | 1996 |
| Target Price: | $150.18 | AVG Volume (30 days): | 848.7K |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.65 | EPS Growth: | 498.36 |
| 52 Week Low/High: | $89.04 - $148.37 | Next Earning Date: | 05-01-2024 |
| Revenue: | $1,982,000,000 | Revenue Growth: | 23.99% |
| Revenue Growth (this year): | 19.71% | Revenue Growth (next year): | 16.25% |
Share on Social Networks:
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Delaet Ingrid | NBIX | Chief Regulatory Officer | May 6 '24 | Sell | $140.55 | 273 | $38,370.15 | 7,507 | SEC Form 4 |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Apr 15 '24 | Sell | $133.36 | 7,231 | $964,359.42 | 40,778 | SEC Form 4 |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Apr 15 '24 | Sell | $133.36 | 12,587 | $1,678,660.22 | 40,778 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Mar 21 '24 | Sell | $145.06 | 5,000 | $725,320.00 | 7,507 | SEC Form 4 |
| MORROW GEORGE J | NBIX | Director | Mar 14 '24 | Sell | $139.41 | 20,000 | $2,788,278.00 | 0 | SEC Form 4 |
| MORROW GEORGE J | NBIX | Director | Mar 14 '24 | Sell | $139.42 | 20,000 | $2,788,432.00 | 0 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Mar 13 '24 | Sell | $140.14 | 3,000 | $420,419.40 | 7,507 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Feb 28 '24 | Sell | $135.64 | 2,500 | $339,103.50 | 7,507 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Feb 28 '24 | Sell | $134.62 | 2,500 | $336,550.00 | 7,507 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Feb 28 '24 | Sell | $136.00 | 1,544 | $209,984.00 | 7,507 | SEC Form 4 |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Feb 28 '24 | Sell | $135.51 | 273 | $36,994.23 | 7,507 | SEC Form 4 |
| POPS RICHARD F | NBIX | Director | Feb 20 '24 | Sell | $132.47 | 15,000 | $1,987,047.00 | 29,512 | SEC Form 4 |
| Lippoldt Darin | NBIX | Chief Legal Officer | Feb 13 '24 | Sell | $132.99 | 1,098 | $146,028.40 | 39,740 | SEC Form 4 |
| Gano Kyle | NBIX | Chief Business Development Off | Feb 13 '24 | Sell | $132.89 | 1,352 | $179,673.63 | 135,166 | SEC Form 4 |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Feb 13 '24 | Sell | $133.01 | 1,098 | $146,050.36 | 40,616 | SEC Form 4 |
| Onyia Jude | NBIX | Chief Scientific Officer | Feb 13 '24 | Sell | $132.94 | 1,432 | $190,371.08 | 13,128 | SEC Form 4 |
| GORMAN KEVIN CHARLES | NBIX | Chief Executive Officer | Feb 13 '24 | Sell | $133.02 | 2,832 | $376,700.46 | 514,596 | SEC Form 4 |
| Boyer David W. | NBIX | Chief Corp. Affairs Officer | Feb 6 '24 | Sell | $141.96 | 240 | $34,070.40 | 5,110 | SEC Form 4 |
| Boyer David W. | NBIX | Chief Corp. Affairs Officer | Feb 6 '24 | Sell | $141.96 | 216 | $30,663.36 | 4,894 | SEC Form 4 |
| Boyer David W. | NBIX | Chief Corp. Affairs Officer | Feb 6 '24 | Sell | $134.19 | 700 | $93,932.30 | 5,523 | SEC Form 4 |
| Boyer David W. | NBIX | Chief Corp. Affairs Officer | Feb 6 '24 | Sell | $136.78 | 628 | $85,897.84 | 4,895 | SEC Form 4 |
| Cooke Julie | NBIX | Chief Human Resources Officer | Feb 6 '24 | Sell | $142.17 | 640 | $90,989.76 | 17,838 | SEC Form 4 |
| Cooke Julie | NBIX | Chief Human Resources Officer | Feb 6 '24 | Sell | $141.96 | 575 | $81,627.00 | 17,263 | SEC Form 4 |
| Cooke Julie | NBIX | Chief Human Resources Officer | Feb 6 '24 | Sell | $134.23 | 700 | $93,960.86 | 17,892 | SEC Form 4 |
| Cooke Julie | NBIX | Chief Human Resources Officer | Feb 6 '24 | Sell | $136.78 | 629 | $86,034.62 | 17,263 | SEC Form 4 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing
PR Newswire
4 days ago
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
Investor's Business Daily
9 days ago
How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
PR Newswire
9 days ago
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
PR Newswire
9 days ago
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
PR Newswire
10 days ago
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
PR Newswire
11 days ago
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
PR Newswire
11 days ago